HAVANA, June 24 (Reuters) - Cuban scientists said on Tuesday the first vaccine to extend lives of lung cancer patients has been approved by Cuban authorities for use and is available in the island's hospitals.
The drug, CimaVax EGF, has been shown to increase survival rates on average four to five months and much longer in some patients, they said in a news conference at Cuba's Center of Molecular Immunology.
In contrast to chemotherapy, the traditional treatment for lung cancer, they said CimaVax EGF has few side effects because it is a modified protein that attacks only cancer cells.
The drug has been approved for clinical trial in the United States, but its possible use there is at least two to three years away, Gonzalez said.
No comments:
Post a Comment